Biotechnology in Switzerland

Geneva Biotech

Geneva Biotech is a privately held biotechnology company, based in Geneva, Switzerland. We are a research focused SME with a vision to develop a portfolio of viral and nonviral DNA delivery systems that provide new and better ways to deliver DNA into cells.

11 to 50 staff

Hepta Group

HEPTA is fully industrializing the production of green energy from biomass. Our competitive advantage gives us the Flexibility to source and deliver On-time Large-Scale volumes of woodchips, of the requested Quality, with attractive Pricing, as a catalyst for the development of large-scale biomass plants. Long-term experience in biomass power plant consulting with the aim of providing such services to clients who are interested in using the 2nd generation bio-ethanol technology.

1 to 10 staff

Matterhorn Biosciences

Matterhorn is a leader in developing a new class of MR1 directed cell therapy targeting cancer through its proprietary M-TCR cell therapy platform.

11 to 50 staff

Bordier Affinity Products Sa

1 to 10 staff

Hygiene Of Sweden

Developers of safe, high quality hygiene products for everyday and professional use. Our non-alcoholic formula is effective against corona- and norovirus.

1 to 10 staff

Biotalk Gmbh

We provide hands-on services to companies with growth opportunities such as start-ups, companies in a turnaround situation, or SMEs with growth projects in general.

1 to 10 staff

Liposmart Ufat - Your Healing Harmony

The human fat holds promise for unprecedented regenerative solutions in multifaced fields, spanning from the esthetic medicine to the treatment of osteoarthritis, up to the handling of severe peripheral vascular diseases, pressure ulcers and intestinal fistula, just to mention some of the ongoing applications. From the initial belief that the regenerative potential of the adipose tissue was only relying upon its own stem cells, we are now aware that these elements work in concert with their own microenvironment, the stromal vascular niche. The preservation of such environmental cues allows adipose stem cells (ADSCs) operating through a “slow releasing medium”, providing the recipient tissue with a wide-ranging profile of regenerative factors where, and when they are mostly needed. From these premises it’s clear that A New Science of Fat Grafting is needed! To satisfy this unmet need, we have now created liposmart®, a new generation of fat processing systems fulfilling a major Conductor Theme: Making readily available a Unified Fat Tissue (UFAT) derivative, recapitulating within a single product all the traits that compose the biophysical properties of the original fat tissue. We can give back your own UFAT, your own adipose tissue in its regenerative fullness. Moreover, the flexible design of the LIPOSMART SYSTEM can provide both a microfragmented fat, or a softer, non-fragmented fat tissue derivative, embedding a seamless stromal vascular niche. These unique features allow adapting the stiffness of LIPOSMART UFAT to the visco-elastic properties of the recipient tissues, resulting in both unprecedented regenerative outcomes and handling amenability by the Surgeons. Even more intriguing, the multimodal conception and design of the LIPOSMART System, can provide personalized solutions, including the release of UFAT or a tissue product embedding its individual components in various combinatorial forms.

1 to 10 staff

Geneuver Biologics

GENeuver uses multiple machine learning methods to help researchers in identifying genetic variations that are associated with physiological implication. We employ multiple algorithms defined based on patterns identified in public genomic datasets and mapped these patterns to reported phenotypic in various population and patient groups. Our algorithms also allow researchers to narrow down choices of target sequences with predictable outcomes. We believe our approach significantly reduce the time, cost and effort necessary for gene editing using CRISPR.

11 to 50 staff

Nuvamid

Launched in Lausanne in 2019, Nuvamid is a clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases. Nuvamid’s Swiss team has developped a unique expertise with endogenous molecules to offer breakthrough therapeutics for the treatment of rare blood diseases. In cooperation with leading partners and institutions in Switzerland (Lausanne University), France (EFS, INSERM, CNRS), and the USA (Buck Institute), Nuvamid has aquired a unique knowledge in blood cells disorders. Our lead molecule NUV01, is currently evaluated in three Phase 2 trials. Nuvamid’s research is built upon the emerging scientific findings linking age-related disease pathologies with NAD metabolism. Nuvamid designed novel NAD metabolism modulators and gathered extensive preclinical data to develop a portfolio of drugs targeting immune disorders.

11 to 50 staff

Omne Possibile

Omne Possibile is a pioneering, global technological leader in XNA, creating customizable structures to outperform current DNA and RNA technologies. Its goal is to harness the transformative power of XNA in areas including healthcare, information technology and smart materials. The Company’s initial focus is on development of XNA polymers for information storage and XNA building blocks for improved messenger therapeutics. Omne Possibile has R&D hubs in Leuven, Belgium, and Basel, Switzerland. It was founded by leading European synthetic biologists and is supported by a world class scientific advisory board. For more information, please visit

11 to 50 staff

Altium

Altium was established in 1997 to provide tailored, turnkey solutions, primarily for the life sciences and analytical chemistry industries. We provide innovative answers to client requirements, from clinical and laboratory project management, the biotechnology, agriculture and pharmaceutical industries to academia. As a privately held investment company with a head office near the city of Lausanne in Switzerland, we have subsidiaries in Poland, the Czech Republic, Croatia, Bosnia & Herzegovina, Romania and Turkey, with third party representation in Azerbaijan and Kosovo. We also maintain a close network of associates throughout Central and Eastern Europe, the Middle East and Africa.

501 to 1000 staff

Neovii

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

51 to 200 staff

Green Logic

At Green Logic, our mission is to create a sustainable future by harnessing the power of Pawlonia tree planting and sustainable investment. As European leaders in both areas, we strive to combat climate change, preserve natural forests, and facilitate environmental recovery. By integrating sustainable investment strategies, we not only generate financial returns but also drive positive environmental impact. Together, let's sow the seeds of a greener tomorrow and nurture a thriving planet.

11 to 50 staff

Qbdc Gmbh

QBDC GmbH (Quality Biotech Development & Cells) is a Switzerland-based, internationally active biopharma consultancy company with the focus on interface management. We are experts in building “bridges”, which facilitate our clients' passage across technological, and cultural gaps, and provide aide in constructing strong and sturdy GMP foundations. Our vast experience in various biotech topics allow us to help our customers recognize and address risks before they become severe, help them prepare for looming challenges, and help them optimize their workflows to reduce time and costs. The topics of our services are CMC development, scale-up and tech transfer, facility design & layout, QC & QA, and project management, and we work with Biosimilars, NBEs, and ATMPs. Apart from our services, we provide a number of customer-tailored solutions: As there are a severe lack of affordable GMP-capable or -compliant digital data and document management systems, we have developed a database software for managing experimental data (METIS) and a document management system for digital documents. The latter is a fully validated (i.e. part11-compliant) application.

1 to 10 staff

Versameb Ag

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct, and cellular targeting. Based in Basel and fully operational from 2018, the company is led by an experienced scientific and leadership team with proven expertise in drug discovery and development from lab bench to patient. Versameb’s proprietary technology platform, VERSagile, optimizes the application of functional RNA in different disease contexts – making RNA druggable in new therapeutic areas others have been unable to solve. The pipeline includes lead candidate programs in Stress Urinary Incontinence (SUI) and solid tumors. Versameb is working towards the completion of a first in-human/proof-of-concept clinical study while advancing its platform.

11 to 50 staff

Discoveric Bio Group

The purpose of the Company is the research, development, licensing, and marketing of medical therapies, in particular for antibody-based therapies of neurological diseases, infectious diseases, cancer diseases and diseases of the immune system.

11 to 50 staff

Abim - Annual Biocontrol Industry Meeting

As the unrivalled meeting place for the biocontrol industry, ABIM is internationally recognised as the venue at which to discover and unveil new products, to discuss market opportunities, to present new research, to learn about the latest regulatory situation and to liaise with fellow professionals from all over the world. During the three days over delegates from 60 countries representing more than 500 companies and organisations from all over the globe can be expected to attend to network and exchange experiences and obtain information on the latest products and developments on the world market. Held in the Congress Center Basel each October.

1 to 10 staff

Caland Sa

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements. A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services. Products: Plant-based (i.e. cannabis, etc.) API, semi-finished, distillate, isolate, formulation, terpenes. All products free of active or residual contamination, solvent, additive. Services: CDMO, API, OEM, White Label, tailored products. Technology: ISO9001, 100% traceable, sub/supercritical CO2, ISO17025 inspection.

11 to 50 staff

Mabewo Phytopharm Ag

MABEWO PHYTOPHARM AG arbeitet mit wissenschaftlichem Fokus an der Entwicklung von stabilen Pflanzengenetiken und Herstellungsprozessen nach GACP & GMP für die Herstellung von Phytopharmaka. Zudem wird eine zertifizierte Produktbaureihe im Bereich Anlagentechnik für Verarbeiter im Bereich GACP & GMP, der Pharma-Dome, entwickelt und vermarktet.

1 to 10 staff

Ct Innovations Ag

Wir haben uns zur Aufgabe gemacht, die Welt mit jedem unserer Produkte und Dienstleistungen ein Stück sicherer, nachhaltiger und sauberer zu machen. Dabei schützen wir die Umwelt und den Menschen mit zahlreichen Lösungsmodellen vor den Gefahren im Alltag, Arbeitsleben und allen anderen Bereichen des gesellschaftlichen Miteinanders.

11 to 50 staff

Evlabio

EvlaBio is a biotech company, focused on the development of a therapy addressing a high unmet medical need in the cardiorenal space. Specifically, we are addressing Left Ventricular Hypertrophy (LVH) in the setting of chronic kidney disease, which affects millions of patients and for which there are limited treatment options.

1 to 10 staff

Infys

1 to 10 staff

Daygnostics Ag

daygnostics commits to delivering solutions for accurate and fast pathogen detection in non-human applications. Our priority is to support industrial partners in providing food of the highest standard and quality to their consumers.

11 to 50 staff

Stc-Science Sàrl

STC science has been founded in 2014 and is located in Switzerland. The idea of this company came from two observations made by biotechnology and healthcare professionals- People in a therapeutic impasse situation will die because of a lack of access to innovative compassionate treatments - To many encouraging and potentially helpful technologies will never reach the market due to the high costs of validation and approval procedures Initially our company focussed on human treatments; we quickly realized that veterinary and environmental extension could be useful. Our network is composed of scientists, engineers and medical doctors with a high level of expertise in their respective field. Aside of STC science’s team, we are permanently growing our network to get access to the right person to answer each question.

1 to 10 staff